Analyst Reco. C4 Therapeutics, Inc.

Equities

CCCC

US12529R1077

Market Closed - Nasdaq Other stock markets 21:00:00 26/04/2024 BST			5-day change	1st Jan Change
6.17 ^USD	-1.12%		-8.18%	+9.20%

04-08	C4 Therapeutics, Inc. Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024	CI
03-18	C4 Therapeutics, Inc.(NasdaqGS:CCCC) added to S&P Biotechnology Select Industry Index	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Morgan Stanley Adjusts Price Target on C4 Therapeutics to $8 From $1, Maintains Equal-Weight Rating	02-26	MT
JPMorgan Upgrades C4 Therapeutics to Neutral From Underweight, Price Target is $6	01-29	MT
Stifel Upgrades C4 Therapeutics to Buy From Hold, Raises Price Target to $12 From $2	12-13	MT
Morgan Stanley Upgrades C4 Therapeutics to Equalweight From Underweight, Cuts Price Target to $1 From $3	11-06	MT
BMO Capital Adjusts Price Target on C4 Therapeutics to $16 From $18, Keeps Outperform Rating	11-03	MT
HC Wainwright Adjusts Price Target on C4 Therapeutics to $7 From $17, Keeps Buy Rating	11-02	MT
HC Wainwright Adjusts Price Target on C4 Therapeutics to $17 From $25, Maintains Buy Rating	09/08/23	MT
UBS Adjusts C4 Therapeutics Price Target to $20 From $22, Maintains Buy Rating	21/07/23	MT
Evercore ISI Adjusts C4 Therapeutics Price Target to $10 From $20, Maintains Outperform Rating	30/05/23	MT
Morgan Stanley Adjusts Price Target on C4 Therapeutics to $3 From $5, Maintains Underweight Rating	12/05/23	MT
HC Wainwright Adjusts C4 Therapeutics' Price Target to $25 From $35, Keeps Buy Rating	08/05/23	MT
BofA Securities Lowers Price Target on C4 Therapeutics to $5 From $11, Maintains Neutral Rating	28/03/23	MT
Morgan Stanley Adjusts Price Target on C4 Therapeutics to $5 From $6, Maintains Underweight Rating	27/02/23	MT
UBS Adjusts C4 Therapeutics Price Target to $22 From $24, Maintains Buy Rating	24/02/23	MT
JPMorgan Chase Downgrades C4 Therapeutics to Underweight From Neutral, Lowers Price Target to $5 From $15	24/02/23	MT
Wells Fargo Adjusts Price Target on C4 Therapeutics to $11 From $12, Maintains Equal-Weight Rating	08/11/22	MT
UBS Adjusts C4 Therapeutics Price Target to $24 From $26, Maintains Buy Rating	04/11/22	MT
JPMorgan Downgrades C4 Therapeutics to Neutral From Overweight, Adjusts Price Target to $15 From $22	04/11/22	MT
Morgan Stanley Starts C4 Therapeutics at Underweight With $6 Price Target	11/10/22	MT
Credit Suisse Raises C4 Therapeutics' Price Target to $12 from $10, Keeps Underperform Rating	05/08/22	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. C4 Therapeutics, Inc.

Equities

CCCC

US12529R1077

Analyst Reco.

Filters